Congratulations to our client Acadia Pharmaceuticals for appointing Shams Zaman as Head of AI Strategy & Enablement.
Acadia Pharmaceuticals is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference.
C1 Team: Tom Barnes, Tom Murphy, & James Reynolds